Minerva Neurosciences is a Burlington clinical-stage company that spent years trying to turn roluperidone into the first approved therapy for the negative symptoms of schizophrenia, only to receive a Complete Response Letter that sent the program back into a confirmatory trial. The investment debate is no longer whether the molecule has a signal. The debate is whether a redesigned late-stage study, financed by a large preferred-and-warrant private placement, can convert a rejected application into an approvable monotherapy package, or whether the equity is a long-duration option on a drug that already failed to separate from placebo on its last registrational primary endpoint.
The October private placement recapitalized a balance sheet that had been running toward empty and put specialist healthcare funds in the cap table with board and scientific-advisory rights. That capital is now being spent. The confirmatory study screened its first patient in March, and a scientific advisory board of psychiatry specialists was stood up in June to police rating quality. Research spending in the June quarter reached $7 million as sites opened. Cash, cash equivalents, marketable securities and restricted cash still sit near $75 million after the first half of trial spend. GAAP results remain almost unreadable because the warrant liability marks to market each quarter, flipping the second quarter into reported profit even as the operating loss widened.
The counterargument is simple and serious. The prior registrational study missed its primary in the intent-to-treat set, the agency asked for more than a single extra statistical comparison, and remaining preferred warrants plus an unused at-the-market program sit over a share count that already expanded several-fold when preferred converted. What resolves the case is whether enrollment stays clean enough for a late-decade efficacy readout to be interpretable, and whether cash lasts that long without another heavily structured raise.